1. Academic Validation
  2. Caprazamycins: Biosynthesis and structure activity relationship studies

Caprazamycins: Biosynthesis and structure activity relationship studies

  • Int J Med Microbiol. 2019 Jul;309(5):319-324. doi: 10.1016/j.ijmm.2019.05.004.
Franziska Wiker 1 Nils Hauck 1 Stephanie Grond 2 Bertolt Gust 3
Affiliations

Affiliations

  • 1 Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, 72076 Tübingen, Germany.
  • 2 Institute of Organic Chemistry, University of Tübingen, 72076 Tübingen, Germany.
  • 3 Pharmaceutical Biology, Pharmaceutical Institute, University of Tübingen, 72076 Tübingen, Germany. Electronic address: [email protected].
Abstract

Cell wall biosynthesis represents a valid target for Antibacterial action but only a limited number of chemical structure classes selectively interact with specific enzymes or protein structures like transporters of the cell envelope. The integral membrane protein MraY translocase is essential for peptidoglycan biosynthesis catalysing the transfer of the peptidoglycan precursor phospho-MurNAc-pentapeptide to the lipid carrier undecaprenyl phosphate, thereby generating the cell wall intermediate lipid I. Not present in eukaryotic cells, MraY is a member of the superfamily of yet not well-understood integral membrane enzymes which involve proteins for Bacterial lipopolysaccharide and teichoic acid or eukaryotic N-linked Saccharides biosynthesis. Different natural nucleoside Antibiotics as inhibitors of MraY translocase have been discovered comprising a glycosylated heterocyclic pyrimidin base among other potential lipid-, peptidic- or sugar moieties. Caprazamycins are liponucleoside Antibiotics isolated from Streptomyces sp. MK730-62F2. They possess activity in vitro against Gram-positive bacteria, in particular against the genus Mycobacterium including M. intracellulare, M. avium and M. tuberculosis. Structural elucidation revealed the (+)-caprazol core skeleton as a unique moiety, the caprazamycins share with other MraY inhibitors such as the liposidomycins, A-90289 and the muraminomicins. They also share structural features such as uridyl-, aminoribosyl- and fatty acyl-moieties with other MraY translocase inhibitors like FR-900493 and the muraymycins. Intensive studies on their biosynthesis during the last decade identified not only common initial biosynthetic steps, but also revealed possible branching points towards individual biosynthesis of the respective compound. Structural diversity of caprazamycins was generated by feeding experiments, genetic engineering of the biosynthetic gene clusters and chemical synthesis for structure activity relationship studies with its target, MraY translocase.

Keywords

Caprazamycins; MraY translocase; Peptidoglycan biosynthesis.

Figures
Products